Clinical trials: Neuroendocrine Tumors, NET
Neuroendocrine Tumors, Gep Net
Observational Study on GEP-and Pulm-NET Treated at FPG
Observational ambispective monocentric study on the clinical, laboratory, pathological and molecular characteristics of patients suffering from gastroenteropancreatic tract and pulmonary neuroendocrine tumors and their prognostic…
- Conditions
- Neuroendocrine Tumors, Gep Net, Pulmonary Neuroendocrine Neoplasm
- Trial name
- ETNA-FPG (NCT06402695)
- Where
- Italy
- Volunteers
- 650 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
The goal of this phase 0 proof-of concept study is to measure the therapeutic index (tumour to dose-limiting-organ dose ratios) of 161Tb-DOTA-LM3 in comparison to the current standard 177Lu-DOTATOC in the same…
- Trial name
- Beta plus (NCT05359146)
- Testing
- 161Tb-DOTA-LM3, 177Lu-DOTATOC
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Basel, Switzerland
Neuroendocrine Tumors, NET
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January…
- Trial name
- NCT01763554
- Testing
- Lu-177 DOTA-TATE
- Where
- Canada
- Volunteers
- 115 people
- Sponsor
- AHS Cancer Control Alberta
GEP-NET, Neuroendocrine Tumors
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
- Conditions
- GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
- Trial name
- NCT05709171
- Testing
- 18F-FDG, 64Cu-Dotatate
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Neuroendocrine Tumors (NET)
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging [including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available]
- Trial name
- NCT05673031
- Testing
- 68Ga-HA-DOTATATE PET/CT imaging
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Alberta Health services
Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC)
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine…
- Trial name
- NCT04525638
- Testing
- 177Lu-Dotatate, Nivolumab
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Advanced NET of GI Origin, Advanced NET of Lung Origin
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of…
- Conditions
- Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
- Trial name
- RADIANT-4 (NCT01524783)
- Testing
- Everolimus, Best suportive care (BSC)
- Where
- 97 sites in United States, Austria and 23 more
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)
Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia
Numerous studies describe HRQoL in other cancer types, whereas only sparse research has been done in NEN patients. We wish to investigate HRQol in NEN patients.
- Trial name
- NCT04557137
- Testing
- Somatostatin analog
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Carcinoid Tumors, Pancreatic NET
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs).
- Trial name
- NCT02575300
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Carcinoid Tumors, Islet Cell (Pancreatic NET)
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing…
- Conditions
- Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
- Trial name
- NCT01980732
- Testing
- 68Ga-DOTA TATE
- Where
- United States
- Sponsor
- Andrei Iagaru